Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PREP | P48147 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14371776 | 1.00 | ALDH1A1 (0.32) | ALDH1A1PREPCHRM2CHRM1CHRM3 | |
| SCHEMBL5160587 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPT | |
| SCHEMBL6178048 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPT | |
| SCHEMBL5412847 | 0.81 | GPR119 (0.34) | ALDH1A1PREPCHRM2CHRM1CHRM3 | |
| SCHEMBL14371767 | 0.81 | GCK (0.31) | GCK | |
| Hydrochloric Acid SCHEMBL5160519 | 0.81 | ALDH1A1 (0.42) | ALDH1A1MAPT | |
| SCHEMBL5158330 | 0.80 | SCN5A (0.31) | ALDH1A1MAPTHPGD | |
| SCHEMBL14371755 | 0.79 | ALDH1A1 (0.30) | ALDH1A1GCK | |
| SCHEMBL5160579 | 0.78 | CYP1A2 (0.37) | ALDH1A1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL14371739 | 0.78 | GCK (0.32) | ALDH1A1GCKGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ALDH1A1 471/4885PREP 2026/4885CHRM2 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.